28 February 2021
EMA/PDCO/144922/2021
Human Medicines Division

PDCO monthly report of opinions on paediatric investigation plans and other activities

23-26 February 2021

Opinions on paediatric investigation plans

The Paediatric Committee (PDCO) adopted opinions agreeing paediatric investigation plans (PIPs) for the following medicines:

- Ritlecitinib, EMEA-002451-PIP01-18, from Pfizer Europe MA EEIG, for the treatment of alopecia areata;
- Surufatinib, EMEA-002750-PIP01-19, from Hutchison MediPharma Ltd, for the treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours and myeloid neoplasms) and treatment of malignant neoplasms of haematopoietic and lymphoid tissue;
- Pioglitazone (hydrochloride) / Spironolactone / metformin (hydrochloride), EMEA-002187-PIP01-17, from Katholieke Universiteit Leuven (KUL) Research & Development, for the treatment of polycystic ovary syndrome;
- Zilucoplan, EMEA-002747-PIP01-20, from UCB Pharma SA, for the treatment of myasthenia gravis;
- Adeno-associated virus, serotype 9 (AAV9)-based non-replicating, self-complementary recombinant vector containing an expression cassette for the human ASPA transgene (scAAV9-CB6-hASPAopt), EMEA-002779-PIP01-20, from Aspa Therapeutics, Inc., for the treatment of Canavan disease;
- Chikungunya Virus Virus-Like Particle Vaccine, EMEA-002656-PIP01-19, from Emergent Netherlands B.V., for the chikungunya disease;
- Dupilumab, EMEA-001501-PIP07-20, from sanofi-aventis recherche & développement, for the treatment of chronic spontaneous urticaria;
- Hydroxypropyl-β-cyclodextrin, EMEA-002839-PIP01-20, from Cyclo Therapeutics Inc, for the treatment of Niemann Pick disease type C;
- Ruxolitinib (phosphate), EMEA-002618-PIP02-20, from Incyte Biosciences Distribution B.V., for the treatment of vitiligo;

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

- Sepofarsen, EMEA-002717-PIP02-20, from ProQR Therapeutics, for the treatment of Leber congenital amaurosis;
- Severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS)/matrix-M1 adjuvant, 002941-PIP01-20, from Novavax, Inc., for the prevention of coronavirus disease 2019 (COVID-19).

A PIP sets out a programme for the development of a medicine in the paediatric population. The PIP aims to generate the necessary quality, safety and efficacy data through studies to support the authorisation of the medicine for use in children of all ages. These data have to be submitted to the European Medicines Agency, or national competent authorities, as part of an application for a marketing authorisation for a new medicine, or for one covered by a patent. In some cases, a PIP may include a waiver of the studies in one or more paediatric subsets, or a deferral.

Opinions on product-specific waivers

The PDCO adopted positive opinions for product-specific waivers, recommending that the obligation to submit data obtained through clinical studies with children be waived in all subsets of the paediatric population, for the following medicines:

- Sabatolimab, EMEA-002931-PIP01-20, from Novartis Europharm, for the treatment of myelodysplastic syndromes;
- Talazoparib, EMEA-002066-PIP02-20, from Pfizer Europe MA EEIG, for the treatment of breast malignant neoplasms and treatment of prostate malignant neoplasms;
- Sutimlimab, EMEA-002542-PIP03-20, from Genzyme Europe B.V., for the treatment of cold agglutinin disease;
- Ensartinib, EMEA-002937-PIP01-20, from Xcovery Holdings, Inc., for the treatment of non-small-cell lung cancer;
- Sintilimab, EMEA-002919-PIP01-20, from Eli Lilly and Company Limited, for the treatment of lung cancer;
- Tavapadon, EMEA-002920-PIP01-20, from Cerevel Therapeutics, LLC, for the treatment of Parkinson's disease;
- Nadofaragene firadenovec, EMEA-002376-PIP02-20, from Ferring Pharmaceuticals A/S, for the treatment of malignant bladder neoplasms;
- Paclitaxel, EMEA-002894-PIP01-20, from Athenex Inc., for the treatment of soft tissue sarcoma;
- Fluoride 18-labelled Prostate-Specific Membrane Antigen-1007 ([18F]PSMA-1007), EMEA-002918-PIP01-20, from ABX advanced biochemical compounds Biomedizinische Forschungsreagenzien GmbH, for the visualisation of prostate specific membrane antigen in prostate cancer;
- Oxygen / Argon, EMEA-002921-PIP01-20, from Air Liquide Santé International, for the treatment of acute ischaemic stroke due to large intracranial vessel occlusion after thrombectomy;
- 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate, EMEA-002923-PIP01-20, from Constellation Pharmaceuticals Inc., for the treatment of myelofibrosis;
- Anti-IL-7Rα monoclonal antibody (S95011/ OSE-127), EMEA-002930-PIP01-20, from Les Laboratoires Servier, for the treatment of Sjögren's syndrome;

- Encequidar, EMEA-002913-PIP01-20, from Athenex Inc., for the treatment of breast cancer and treatment of soft tissue sarcoma;
- Anti-alpha-synuclein human monoclonal antibody, EMEA-002936-PIP01-20, from H. Lundbeck A/S, for the treatment of Multiple System Atrophy and treatment of Parkinson's disease;
- Humanised recombinant IgG4, Anti-PD-1 monoclonal antibody (CS1003), EMEA-002939-PIP01-20, from CStone Pharmaceuticals (Suzhou) CO., Ltd., for the treatment of hepatocellular carcinoma;

Waivers can be issued if there is evidence that the medicine concerned is likely to be ineffective or unsafe in the paediatric population, or that the disease or condition targeted occurs only in adult populations, or that the medicine, or the performance of trials, does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

Opinions on modifications to an agreed PIP

The PDCO also adopts, every month, opinions on modifications to an agreed PIP, which can be requested by the applicant when the plan is no longer appropriate or when there are difficulties that render the plan unworkable. The PDCO adopted positive opinions, agreeing change(s), for the following products:

- Oritavancin (diphosphate), EMEA-001270-PIP01-12-M03, from Menarini International Operations Luxembourg S.A., for the treatment of acute bacterial skin and skin structure infections;
- Mometasone (furoate) / Indacaterol (acetate), EMEA-001217-PIP01-11-M07, from Novartis Europharm Limited, for the treatment of asthma;
- Landiolol (hydrochloride), EMEA-001150-PIP02-13-M04, from AOP Orphan Pharmaceuticals AG, for the treatment of supraventricular arrythmias;
- Gadopiclenol, EMEA-001949-PIP02-18-M01, from Guerbet, for the detection and visualization of disorders or lesions with suspected abnormal vascularity in various body regions for diagnostic purposes;
- Volanesorsen, EMEA-001915-PIP01-15-M03, from Akcea Therapeutics, for the treatment of familial chylomicronemia syndrome;
- Valoctocogene roxaparvovec, EMEA-002427-PIP01-18-M01, from BioMarin International Limited, for the treatment of Haemophilia A;
- Golimumab, EMEA-000265-PIP02-11-M03, from Janssen Biologics B.V., for the treatment of Ulcerative Colitis;
- Upadacitinib, EMEA-001741-PIP01-14-M04, from AbbVie Ltd, for the treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis);
- Tenofovir (disoproxil fumarate), EMEA-000533-PIP01-08-M10, from Gilead Sciences International Limited, for the treatment of chronic viral hepatitis B and treatment of human immunodeficiency virus (HIV-1) infection;
- Bimekizumab, EMEA-002189-PIP01-17-M02, from UCB Biopharma SRL, for the treatment of psoriasis;
- Ethinyl estradiol / Dienogest, EMEA-002229-PIP01-17-M02, from Chemo Research, for the contraception;

- Ladarixin, EMEA-002642-PIP01-19-M03, from Dompé farmaceutici S.p.A, for the treatment of type 1 diabetes;
- Defatted powder of peanuts, EMEA-001734-PIP01-14-M05, from Aimmune Therapeutics Inc, for the treatment of peanut allergy;
- Maralixibat Chloride, EMEA-001475-PIP02-13-M01, from Mirum Pharmaceuticals, for the treatment of Alagille syndrome;
- Azilsartan medoxomil, EMEA-000237-PIP01-08-M09, from Takeda Development Centre Europe Ltd, for the treatment of hypertension;
- Gadopiclenol, EMEA-001949-PIP01-16-M04, from Guerbet, for the detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes;
- Potassium chloride / Sodium chloride / Citric acid (as citric acid anhydrous) / Sodium citrate / Simeticone / Sodium sulphate (as sodium sulfate anhydrous) / Macrogol 4000, EMEA-001356-PIP02-12-M04, from Alfasigma S.p.A., for bowel cleansing prior to clinical procedures;
- Dermatophagoides farinae / Dermatophagoides pteronyssinus, EMEA-001258-PIP01-11-M07, from ALK-Abelló A/S, for the treatment of allergic rhinitis and treatment of asthma;
- Upadacitinib, EMEA-001741-PIP04-17-M02, from AbbVie Ltd, for the treatment of atopic dermatitis;

Opinion on compliance check

The PDCO adopted positive opinions on (full) compliance check for:

- Cerliponase alfa, EMEA-C-001362-PIP01-12-M03, from BioMarin International Limited, for the treatment of Neuronal Ceroid Lipofuscinosis Type 2 (NCL2);
- Sofosbuvir / Velpatasvir, EMEA-C-001646-PIP01-14-M02, from Gilead Sciences Ireland UC, for the treatment of chronic hepatitis C;

A compliance check is performed to verify that all the measures agreed in a PIP and reflected in the Agency's decision have been conducted in accordance with the decision, including the agreed timelines. Full compliance with all studies/measures contained in the PIP is one of several prerequisites for obtaining the rewards and incentives provided for in Articles 36 to 38 of the Paediatric Regulation.

Before the submission of a request for a compliance check, applicants are encouraged to consult the Agency's Procedural advice for validation of a new marketing authorisation application or extension/variation application and compliance check with an agreed PIP.

Withdrawals

The PDCO noted that 3 applications were withdrawn during the late stages of the evaluation (30 days or less before completion of the procedure).

Other matters

The PDCO welcomed Johannes Taminiau as a new member and Fabio Midulla as a new alternate representing Healthcare professionals nominated by the European Commission. Tereza Bazantova has been nominated as the new alternate for Czech Republic.

The next meeting of the PDCO will be held on 23-26 March 2021.

Notes:

1. As of 26 January 2009, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product, or those that submit an application for an extension of indication, a new route of administration, or a new pharmaceutical form of a medicinal product already authorised in the European Union, have to provide either the results of studies in children conducted in accordance with an approved PIP, or an Agency's decision on a waiver or on a deferral.

2. PDCO opinions on PIPs and waivers are transformed into Agency's decisions within the timeframe laid down by the Paediatric Regulation (Regulation (EC) No 1901/2006, as amended). The decisions can be found on the Agency's website at:
   https://www.ema.europa.eu/en/medicines/ema_group_types/ema_pip

   More information about the PDCO and the Paediatric Regulation is available in the Regulatory section of the Agency's website:

   https://www.ema.europa.eu/en/committees/paediatric-committee-pdco

   http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000023.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240cd

3. This meeting report, together with other information on the work of the Agency's, can be found on the Agency's website: http://www.ema.europa.eu

Enquiries to: AskEMA (https://www.ema.europa.eu/en/about-us/contact/send-question-european-medicines-agency)